Company Active LTD

Company profile

Sal Scientific Limited

Sal Scientific Limited is a UK company with status active founded in 2013 based in South West England.

CRN
08660648
Founded
2013
Age
12

Overview

Legal name
SAL SCIENTIFIC LIMITED
Region
South West England
Registered address
SOLENT HOUSE JOHNSON ROAD
FERNSIDE BUSINESS PARK
WIMBORNE
DORSET
ENGLAND
BH21 7SE
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

10 events
10 Dec
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

26 Nov
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

26 Nov
2024

Confirmation Statement With No Updates

Confirmation-statement

CS01 | Transaction MzQ0NDk0MTQxNWFkaXF6a2N4

Published 26 Nov 2024 02:51

17 Aug
2024

Gazette Filings Brought Up To Date

Gazette

DISS40 | Transaction MzQzMjE2NjIzNWFkaXF6a2N4 | Paper/PDF filed

Published 18 Aug 2024 07:39

14 Aug
2024

Legacy

Accounts PDF pending

PARENT_ACC | Transaction MzQzMjE2NjAxNWFkaXF6a2N4 | Paper/PDF filed

Published 16 Aug 2024 12:21

14 Aug
2024

Change Account Reference Date Company Previous Shortened

Accounts Awaiting analysis

AA01 | Transaction MzQzMjE4MTU3MWFkaXF6a2N4

Published 14 Aug 2024 17:52

14 Aug
2024

Accounts With Accounts Type Audit Exemption Subsiduary

Accounts PDF pending

AA | Transaction MzQzMjE2NjE5MmFkaXF6a2N4 | Paper/PDF filed

Published 14 Aug 2024 13:59

22 Aug
2013

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2015
Funded years
2015, 2016
Age at first award
1 years

Projects

2016 Collaborative R&D Lead participant

Development of a novel 3D microfluidic assay platform for the assessment of human stem-cell derived epithelial function.

1 Apr 2016 to 30 Sep 2018

Awarded
£210,426
Total cost £350,710

We aim to develop a novel analytical platform for the assessment of stem cell-derived epithelial function. The platform integrates novel microfluidic technology with a 3D stem cell-derived tissue model and a range of analytical outputs and delivers more physiologically relevant data than current in vitro models – uncovering previously unseen responses to ...

2015 Feasibility Studies Lead participant

Novel microfluidic assay platform for the assessment of stem cell-derived epithelial function.

1 Jun 2015 to 30 Sep 2015

Awarded
£23,100
Total cost £33,000

We aim to develop a novel analytical platform for the assessment of epithelial function across a range of tissue types. The platform integrates microfluidic technology with a range of analytical outputs and delivers more physiologically relevant data than current in vitro models – uncovering previously unseen responses to environmental challenge. However,...

Product types

Collaborative R&D Feasibility Studies